Compare with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs BIOCON - Comparison Results

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES BIOCON ALKEM LABORATORIES/
BIOCON
 
P/E (TTM) x - 17.1 - View Chart
P/BV x 6.6 2.6 251.8% View Chart
Dividend Yield % 0.7 0.4 148.7%  

Financials

 ALKEM LABORATORIES   BIOCON
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
BIOCON
Mar-18
ALKEM LABORATORIES/
BIOCON
5-Yr Chart
Click to enlarge
High Rs1,5891,188 133.8%   
Low Rs1,232305 403.9%   
Sales per share (Unadj.) Rs417.568.7 607.4%  
Earnings per share (Unadj.) Rs56.37.6 745.5%  
Cash flow per share (Unadj.) Rs64.714.0 463.2%  
Dividends per share (Unadj.) Rs12.701.00 1,270.0%  
Dividend yield (eoy) %0.90.1 672.1%  
Book value per share (Unadj.) Rs292.986.3 339.3%  
Shares outstanding (eoy) m119.57600.00 19.9%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x3.410.9 31.1%   
Avg P/E ratio x25.198.9 25.3%  
P/CF ratio (eoy) x21.853.4 40.8%  
Price / Book Value ratio x4.88.6 55.7%  
Dividend payout %22.613.2 170.4%   
Avg Mkt Cap Rs m168,653447,900 37.7%   
No. of employees `000NA6.1 0.0%   
Total wages/salary Rs m9,1719,311 98.5%   
Avg. sales/employee Rs ThNM6,705.8-  
Avg. wages/employee Rs ThNM1,514.2-  
Avg. net profit/employee Rs ThNM736.9-  
INCOME DATA
Net Sales Rs m49,91541,234 121.1%  
Other income Rs m1,6452,062 79.8%   
Total revenues Rs m51,56143,296 119.1%   
Gross profit Rs m8,4828,291 102.3%  
Depreciation Rs m1,0063,851 26.1%   
Interest Rs m671615 109.0%   
Profit before tax Rs m8,4515,887 143.6%   
Minority Interest Rs m-114213 -53.4%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,569 102.4%   
Profit after tax Rs m6,7314,531 148.6%  
Gross profit margin %17.020.1 84.5%  
Effective tax rate %19.026.7 71.3%   
Net profit margin %13.511.0 122.7%  
BALANCE SHEET DATA
Current assets Rs m27,06241,486 65.2%   
Current liabilities Rs m15,32421,413 71.6%   
Net working cap to sales %23.548.7 48.3%  
Current ratio x1.81.9 91.2%  
Inventory Days Days6764 104.0%  
Debtors Days Days4194 43.8%  
Net fixed assets Rs m12,61050,661 24.9%   
Share capital Rs m2393,000 8.0%   
"Free" reserves Rs m34,49048,808 70.7%   
Net worth Rs m35,02751,808 67.6%   
Long term debt Rs m1,21217,898 6.8%   
Total assets Rs m54,38799,897 54.4%  
Interest coverage x13.610.6 128.7%   
Debt to equity ratio x00.3 10.0%  
Sales to assets ratio x0.90.4 222.4%   
Return on assets %13.65.2 264.2%  
Return on equity %19.28.7 219.7%  
Return on capital %24.99.6 258.0%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,56312,058 54.4%   
Fx outflow Rs m3,0127,348 41.0%   
Net fx Rs m3,5524,710 75.4%   
CASH FLOW
From Operations Rs m7,2596,621 109.6%  
From Investments Rs m1,864-6,840 -27.3%  
From Financial Activity Rs m-9,273-2,397 386.8%  
Net Cashflow Rs m-150-2,612 5.7%  

Share Holding

Indian Promoters % 66.9 40.4 165.6%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 33.1 8.4 394.0%  
FIIs % 0.0 10.7 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.9 -  
Shareholders   68,381 109,995 62.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   JUBILANT LIFE SCIENCES  PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  PLETHICO PHARMA  

Compare ALKEM LABORATORIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON LTD Announces Quarterly Results (3QFY19); Net Profit Up 169.2% (Quarterly Result Update)

Jan 28, 2019 | Updated on Jan 28, 2019

For the quarter ended December 2018, BIOCON LTD has posted a net profit of Rs 2 bn (up 169.2% YoY). Sales on the other hand came in at Rs 15 bn (up 45.6% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (2QFY19); Net Profit Up 501.9% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, BIOCON LTD has posted a net profit of Rs 4 bn (up 501.9% YoY). Sales on the other hand came in at Rs 13 bn (up 36.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

BIOCON LTD Announces Quarterly Results (1QFY19); Net Profit Up 47.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, BIOCON LTD has posted a net profit of Rs 1 bn (up 47.2% YoY). Sales on the other hand came in at Rs 11 bn (up 20.4% YoY). Read on for a complete analysis of BIOCON LTD's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 20, 2019 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - GSK PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS